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In this review, we discuss the recent identification in vivo of a population of CD11c
þ cells exhibiting simultaneous expression of both
endothelial and dendritic cell markers, termed vascular leukocytes (VLCs). VLCs are highly represented in human ovarian carcinomas
and, depending on the milieu, can assemble into functional blood vessels or act as antigen-presenting cells. The identification of
dendritic cell precursors as bipotent cells has important implications for the physiopathology and therapy of tumours. VLCs emerge as
a novel therapeutic target against tumour vascularisation.
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Tumours require blood supply for expansive growth. Even p53-
null tumour cells, which have a reduced rate of apoptosis, die
beyond an oxygen diffusion limit in the range of 150mm (Folkman,
2002). Therefore, growing tumours require the continual forma-
tion of neovasculature around which tumour cells will proliferate.
These vessels are quite different from vessels of normal tissues,
both at the morphological and molecular levels (Asahara et al,
1997; Ruoslahti, 2002). Until lately, angiogenesis, or sprouting of
endothelial cells from existing vessels, was the only accepted
mechanism of tumour vascularisation. More recent studies
indicated that vasculogenesis, or recruitment of endothelial
progenitors (EPCs) that differentiate into endothelial cells, plays
an important role in the formation of tumour neovessels (Reyes
et al, 2002). The origin of this endothelium may be either bone
marrow-derived EPCs or local EPCs rooted within organs or
vascular parenchyma. Initially, the only source of EPCs was
thought to be a scarce haematopoietic stem-cell containing CD34
þ
population (Rafii, 2000). However, the relative contribution of
bone-marrow-derived EPCs to adult neovascularisation has been
lately underscored, ranging from very little to 450%. Still, Asahara
et al (1997) and Kalka et al (2000) described long before a much
more frequent population of EPCs expanded in vitro from human
peripheral blood. In animal models of ischaemia, these EPCs were
also incorporated into sites of active angiogenesis, suggesting that
a different population of EPCs may significantly contribute to
physiological or pathological vascularisation.
ENDOTHELIAL-LIKE DIFFERENTIATION OF DENDRITIC
CELLS (DCS) IN VITRO
It is well known that in the early embryo haematopoiesis begins in
the blood islands of the yolk sac. Haematopoietic and vascular
development is therefore intimately connected, apparently sharing
a common mesodermal progenitor, the ‘haemangioblast’. Emer-
ging studies have identified a population of primitive endothelial-
like cells derived from human embryonic stem cells that includes
bipotent cells with endothelial and haematopoietic capacity (Wang
et al, 2004). However, until very recently, it was thought that this
close association between haematopoiesis and vascularisation was
restricted to the developing embryo. Already in 2000, Fernandez
Pujol et al (2000) challenged this dogma by showing that CD14
þ
mononuclear cells cultured in the presence of angiogenic growth
factors acquire the markers and morphology of endothelial-like
cells. CD14 is expressed by a myeloid population with a
remarkable plasticity, since it can comprise monocytes, macro-
phages, monocyte-derived DCs, monocyte-derived osteoclasts or
DC-derived osteoclasts (Shortman and Liu, 2002; Rivollier et al,
2004). Similarly, Schmeisser et al (2001) found that a 490% pure
population of CD34
 CD14
þCD45
þCD31
þ leukocytes expressed
endothelial-specific markers after 2 weeks in culture under
angiogenic conditions, forming endothelial-like cords and tubular
structures in three dimensional Matrigel
s.
Although the absence of clonal analysis and studies of
proliferation cannot exclude that a tinny proportion of proliferating
endothelial cells became highly represented in the cultures, these
studies suggested for the first time the existence of a novel subset of
cells with vasculogenic potential. In addition, a phenotypic overlap
between haematopoietic DCs and endothelial cells was soon after
described: Fernandez Pujol et al (2001) found that the same
population of monocyte-derived DCs could exhibit phenotypic
properties of mature DCs under inflammatory conditions, or,
alternatively, behave as endothelial-like cells in an angiogenic
milieu. The process of ‘endothelialisation’ was characterised by a
disappearance of the leukocyte markers CD14, CD1a and CD83, and
the expression of the endothelial markers von Willebrand factor
(vWF), vascular endothelial growth factor receptor-2 (VEGFR-2)
and VE-cadherin. Although the cells exhibited a reduced capacity to
prime T cells, CD86 and major histocompatibility class II (MHC-II)
were expressed at similar levels than in mature DCs. Although the
purity of the culture is again an issue, monocyte-derived DCs
remain in a state of low proliferation, indicating that cultured cells
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that DCs are the closest leukocytes to endothelial cells was provided
by Harraz et al. By culturing a population of CD34
 CD14
þ
monocytes under angiogenic conditions, they observed that, in the
process of endothelialisation, monocytes acquire a DC phenotype,
expressing markers such as endoglin and CD1a (Harraz et al, 2001).
This in vitro differentiated population could be incorporated into
mouse ischemic limbs, although that required coinjection with
CD34
þ cells.
More recently, other studies have confirmed the angiogenic
potential of the monocyte/macrophage/dendritic/osteoclast lineage
in vitro. By using two generally accepted criteria for the isolation of
EPCs, such as uptake of acetylated low-density lipoprotein (LDL)
and binding of ulex-lectin, a CD34
  population expressing
monocyte/macrophage/dendritic markers was isolated from hu-
man peripheral blood (Rehman et al, 2003). Although they
secreted numerous angiogenic factors, these cells did not exhibit
any significant proliferation, suggesting that they may contribute
to neovascularisation mainly through migration and incorporation
into the vascular wall. A more challenging study has reported
pluripotent capabilities for a subset of peripheral blood
CD14
þCD34
þCD45
þ leukocytes. These cells could be isolated
and clonally expanded, giving rise not only to endothelial cells
under angiogenic conditions but also to lymphocytes, macro-
phages, epithelial cells, and even liver cells and neurons under
appropriate conditions (Zhao et al, 2003).
In an effort to understand our surprising findings in an in vivo
model, we have dissected the process of transdifferentiation of
murine bone marrow-derived DCs into cells with markers,
morphology and functional properties of endothelium. We
procured a 497% pure population of CD34
 CD11c
þ DCs by
the classical method of culturing bone-marrow cells in the
presence of granulocyte–macrophage colony-stimulating factor
(GM-CSF). In agreement with their common use as antigen-
presenting cells in immunological studies, DCs obtained in this
way exhibited all the characteristics of canonical DCs, including
dendritic shape, phagocytosis of apoptotic fluorescence-labelled
tumour cells and maturation induced by tumour necrosis factor-
alpha or bacterial lipopolysaccharide in vitro. They also induced
antigen-specific T-cell proliferation, as assessed by
3H-thymidine
incorporation, and secretion of interferon-gamma as well as
interleukin-2 by lymphocytes. Interestingly, CD34
 CD11c
þ cells
cultured in media conditioned by tumour cells expressing high
levels of VEGF assumed a spindle-like shape within 3–5 days of
culture. After 7 days, 5% of CD34
 CD11c
þ cells expressed CD31
by immunohistochemistry, while vWF was still not detectable.
After 3 weeks, more than 80% of the cells expressed CD31 and
vWF, and expressed binding sites for Griffonia simplicifolia B4
lectin. Incubation of CD34
 CD11c
þ immature DCs with tumour
cell-conditioned media led to progressive alignment of single cells
oriented with the same polarity, forming string-like structures
(Figure 1). These grew longitudinally and recruited more cells to
the sides, forming cord-like structures. Video integration showed
that nearby or distant cells migrated towards alignments or cords
of vascular leukocytes (VLCs) adhered to and finally integrated
into cord structures.
By flow cytometry, most cells expressed de novo CD34 and
upregulated CD31 within 1 week. These changes were not due to
overgrowth of a small fraction of contaminating endothelial
progenitors, since the rate of proliferation was very low. Instead,
we theorised that our analyses captured the progressive ‘endothe-
lial-like switch’ of CD11c
þ DCs within the tumour-conditioned
media, so we termed these CD11c
þCD45
þ DCs expressing CD31
and CD34, and exhibiting morphological and molecular properties
of endothelial cells, VLCs. More than 90% of VLCs exhibited
uptake of fluorescent acetylated LDL. Due to the phenotypic
overlap between haematopoietic and endothelial cells, electron
microscopy is still considered the gold standard to determine the
nature of a cell. We have showed that within 3 weeks of culture
with tumour cell-conditioned media, VLCs exhibited Weibel–
Palade bodies and endocytic vesicles. In addition, they created
intercellular junctions, organising themselves around a lumen,
which are typical morphological properties of endothelial cells
(Conejo-Garcia et al, 2004).
Remarkably, VEGF, important for the survival and proliferation
of bona fide endothelial cells, was the critical factor for
endothelialisation. Blocking VEGFR-2 (but not other VEGF
receptors) with neutralising antibodies stopped the transdiffer-
entiation process.
VASCULAR LEUKOCYTES CONTRIBUTE TO TUMOUR
VASCULARISATION
Although these in vitro studies revealed an unsuspected plasticity
of cells from the monocyte/macrophage/dendritic/osteoclast line-
age, it was not clear yet whether these changes took place in vivo,
under physiological or pathological conditions. Moreover,
although VLCs exhibit ultrastructural properties of endothelial
cells, it needed to be proven that they contribute to neovascular-
isation.
Figure 1 Transdifferentiation of bone marrow-derived DCs into
endothelial-like cells in vitro. Most bone marrow-derived DCs aggregate
into cord-like structures after 7 days in culture with tumour cell-
conditioned media. More than 90% of them exhibited uptake of fluorescent
acetylated low-density lipoprotein (top); Details of a cord composed by
bone marrow-derived DCs treated with tumour cell-conditioned media for
2 weeks, which exhibits a cobblestone pattern of cell aggregation (bottom).
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in tumours has been extensively described (Gabrilovich et al, 1996,
1998; Oyama et al, 1998; Ohm et al, 1999): VEGF blocks the
functional maturation of DC from haematopoietic progenitor cells
by blocking NF-kB transcription, although it is unlikely that this
inhibition alone turns these progenitors into endothelial-like cells.
Confirming the critical role of VEGF on tumour immune evasion,
antibodies to VEGF enhance the efficacy of cancer immunotherapy
by improving endogenous dendritic cell function (Gabrilovich et al,
1999). Furthermore, Almand et al (2000) described that high levels
of VEGF in blood result on decreased numbers of competent DCs
and accumulation of immature haematopoietic cells. It is tantalis-
ing to speculate that these cells might exhibit an endothelial-like
phenotype. Nevertheless, the angiogenic potential of DC precursors
remained unsuspected until De Palma et al provided evidence that
naturally occurring immature myeloid cells could be incorporated
into blood vessels in tumours. They transduced bone-marrow
progenitors with lentiviral vectors expressing green fluorescent
protein under the Tie-2 promoter/enhancer, a marker thought to be
endothelial-specific (De Palma et al, 2003). To their surprise,
expression of the Tie2p/e vector identified a subset of
CD45
þCD11b
þTie2
þSca-1
þCD34
þ mononuclear cells that as-
sembled a stromal structure in close association with ‘canonical’
ECs, a possible involvement in vasculogenesis.
In 2001, we viewed DCs only as critical regulators of adaptive
immune responses, including those against tumours. In an attempt
to create a model to study the effects of recruiting DCs
intratumourally on antitumour immune response, we expressed a
newly cloned b-defensin in an ovarian carcinoma cell line ectopically
producing low or high levels of VEGF (Conejo-Garcia et al, 2004). b-
Defensins are antimicrobial peptides that chemoattract immature
DCs through CCR6, thus linking innate and adaptive immunity
(Yang et al, 2004a). By recruiting DCs to tumour sites, we expected
to accelerate phagocytosis and presentation of tumour antigens, thus
potentiating the immune response. We indeed found a massive
accumulation of CD11c
þ cells in flank tumours and tumour ascites.
CD11c is a marker mainly restricted to the DC compartment in the
mouse. More than 90% of CD11c
þCD45
þ cells were MHC-II
þ,
DEC-205
þ and CD8a
þ, documenting their DC lineage, but they
expressed very low levels of costimulatory molecules, and were thus
identified as DC precursors. In tumours expressing physiologic
levels of VEGF (comparable to those found in well vascularised
organs such as kidney), expression of b-defensins reduced tumour
growth in a flank model. However, in the presence of increased
levels of VEGF, chemoattraction of CCR6
þ DC precursors resulted
in a dramatic acceleration of tumour growth and reduced survival
compared to tumours with no b-defensin expression. Although
VEGF was ectopically expressed in our model, its levels resemble
those found in human tumours. Interestingly, tumours expressing b-
defensins appeared markedly more congested and haemorrhagic
compared to controls. They also exhibited a markedly different
architecture, with disorganised accumulations of tumour cells, much
more abundant CD31
þ vessels and scarce stroma. When we
analysed the distribution of CD11c
þ DC precursors by immuno-
histochemistry, they localised to the luminal surface of capillary-like
structures, admixed with CD11c
  cells, indicating that they had
contributed to the increased vascular density.
The frequency of CD11c
þ DC precursors in ascites increased
with neoplastic progression, reinforcing the notion that CD11c
þ
cells may contribute to ovarian carcinogenesis. Similarly to the in
vitro experiments, VEGF demonstrated to be a critical factor for the
acquisition of morphological and functional characteristics of
endothelial cells by DC precursors, since administration of the
tyrosine kinase inhibitor SU5416 (Sugen Inc., San Francisco, CA)
completely abrogated their vascular homing. Strikingly, we identi-
fied for the first time in vivo CD11c
þ cells exhibiting simultaneous
expression of both endothelial and leukocyte markers (VLCs). We
hypothesised that our analyses within the tumour microenviron-
ment mimicked the progressive ‘endothelial-like switch’ of CD11c
þ
leukocytes observed in vitro, which appeared to first acquire CD34,
increase CD31 expression, and progressively lose the expression of
the haematopoietic marker CD45. Tumour-infiltrating VLCs were
highly represented in mouse ascites (430% of total cells). They
expressed markers common to endothelial and dendritic cells, such
as CD31, vWF mRNA and VEGFR-1 (thought to be specific of
endothelial cells); exhibited uptake of acetylated LDL, and bound to
Bandeiraea simplicifolia (BS-1) lectin (our unpublished observa-
tions). Notably, they also exhibited typical endothelial-specific
markers (Rafii and Lyden, 2003), such as VE-cadherin, CD146
(P1H12) and VEGFR-2. More importantly, labelled VLCs trans-
planted in Matrigel plugs in vivo, assembled into tubular structures
formed by fluorescent cells, which were variably perfused with
fluorescent dextran injected through the left cardiac ventricle,
indicating that they had given rise to intact blood-carrying
capillaries in vivo. Additional analysis with fluorochrome-labelled
antibodies revealed that cells forming neovessels retain the
expression of CD11c and CD45, confirming their leukocyte lineage.
Similarly, histological analysis of solid tumour specimens revealed
the presence of CD11c
þ cells at an endothelial location. Although
bona fide endothelial cells can also express CD11c under certain
conditions (Langeggen et al, 2002), we also found numerous CD45
þ
vessels in all the specimens obtained with our tumour model. Of
note, the same cells extracted from dissociated tumour specimens or
tumour ascites were able to induce strong immune responses in
naı ¨ve T cells when treated with a cocktail of inflammatory
molecules, confirming their antigen-presenting cell nature.
The accumulation of immunosuppressor, immature Gr-1
þ cells
in mice with large tumour burdens has been already described
(Kusmartsev et al, 2000), suggesting that tumours naturally recruit
immature myeloid precursors to support their vascularisation.
Supporting this idea, we found a population of CD45
þCD11c
þVE-
cadherin
þCD146
þ VLCs in a murine lung tumour model,
although less represented in the absence of ectopic expression of
b-defensins (unpublished observations). In addition, immature
myeloid Gr1
þCD11b
þ cells have been recently found to
incorporate into tumour endothelium, acquiring endothelial cell
properties (Yang et al, 2004b). These cells are more differentiated
than classical progenitors, representing immature myeloid cells in
an intermediate stage of differentiation. Of note, human tumours
of different origins naturally express high levels of b-defensins,
and ovarian cancer in particular produces other chemokines that
also attract proangiogenic DCs into the tumour microenviron-
ment, such as stroma-derived factor 1 (SDF-1) (Curiel et al, 2004).
Therefore, it was not surprising to find that two different anti-
CD45 antibodies stained tortuous, thorny vascular structures that
were simultaneously positive for vascular markers in human
ovarian carcinoma specimens exhibiting high levels of VEGF and
b-defensins mRNA.
The concept that the formation of blood vessels by DCs with
endothelial potential (VLCs) is not restricted to artificial tumour
models, but rather constitutes a bona fide angiogenic mechanism
promoting the progression of human tumours, is supported by the
high (B40%) proportion of VLCs systematically accumulated in
ovarian carcinomas (Conejo-Garcia et al, 2005). Single-cell
suspensions derived from freshly dispersed human ovarian
carcinomas separate into three clearly isolatable fractions, accord-
ing to their expression of CD45 (leukocyte) and VE-cadherin
(endothelial) markers: bona fide leukocytes (CD45
þVE-cadherin
 ;
mostly lymphocytes according to their FSC vs SSC profile),
bona fide endothelial cells (CD45
 VE-cadherin
þ) and, VLCs
(CD45
þVE-cadherin
þ). We have identified these three popula-
tions in all specimens analysed so far (n¼14), though in different
proportions. Although the high frequency of VLCs in solid
tumours may be caused by the mechanical procedure of
dispersion, it is still surprising that the proportion of VLCs is
comparable to that of non-VLCs.
Vascular leukocytes in tumours
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markers, such as CD146 and CD34. Further characterisation of
VLCs revealed that 490% are MHC-II
þ and CD86
þ, while 486%
express CD11c
þ, compatible with an immature DC phenotype.
Supporting their immature character, 45% of VLCs express
CD133
þ (15–80%), a stem-cell marker with unknown function,
absent in mature endothelium or committed myeloid cells.
Confirming their angiogenic potential, tumour-infiltrating VLCs
have the capacity to create perfusible blood vessels in vivo in
Matrigel plugs. Experiments performed with CCR6-immunotoxins
suggest that the role of VLCs to tumour vasculogenesis takes place
primarily during the early stages of tumour growth. Due to their
limited proliferating capacity, we propose that their angiogenic
potential is mediated mainly by their recruitment to the tumour.
In addition to their capacity to become endothelial-like cells, a
recent study reported the presence of CD11b
þ leukocytes as
periendothelial vascular mural cells (Rajantie et al, 2004). We have
also found CD11c
þ at a periendothelial location in selected
specimens of our tumour model, although they always expressed
CD31, a marker typically absent in classical pericytes. It is likely
that these periendothelial leukocytes contribute to neovascularisa-
tion by secreting angiogenic factors. Alternatively, they may be
VLCs assembling into neovessels branching out, or represent
leukocytes transdifferentiating into pericytes.
VLCS REPRESENT A NOVEL TARGET FOR
IMMUNOTHERAPY
The potential to inhibit tumour growth by targeting VLCs is
illustrated by our studies with CCR6-immunotoxins: Tumours
injected in the presence of anti-CCR6 antibodies bound to saporin,
a ribosomal-inactivating protein, grew 2.6-fold less than tumours
injected with an isotype control antibody. Since decrease in tumour
growth was associated with a reduced number of CD11c
þ infiltrating
cells, VLCs emerge as novel therapeutic targets. Antibodies directed
against specific antigens and conjugated to toxins may contribute to
block tumour vascularisation. On the other hand, we have found a
higher presence of VLCs in the tumour periphery, suggesting that, as
the tumour grows, VLCs stick preferentially around the tumour.
Therefore, VLCs appear as optimal candidates for targeted delivery of
therapeutic agents as ‘Trojan Horses’. For instance, adoptive therapy
of VLCs expressing suicidal genes with bystander effect may help to
collapse tumour neovessels, thus triggering both necrosis and
antitumour immune responses. Alternatively, transduction of VLCs
with vectors expressing immune factors under the control of
endothelial-specific promoters may negate their angiogenic potential
once they have been incorporated into the vessel wall, delivering
inflammatory cytokines into the tumour microenvironment.
TRANSDIFFERENTIATION IN THE TUMOUR
MICROENVIRONMENT OR RECRUITMENT AS DUAL
CELLS?
An important question that remains unresolved is whether VLCs
are directly recruited as cells with ‘haemangioblast’ properties, or
rather as leukocytes in a low stage of differentiation that turn into
dual cells in the tumour microenvironment (Figure 2). Several
studies conducted by our group support the later hypothesis: First,
we have not found CD45
þCD11c
þVE-cadherin
þCD146
þ cells in
peripheral blood of patients with ovarian carcinoma. Similarly, we
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Figure 2 Hypothetical scheme of the transdifferentiation of DC precursors into endothelial-like vascular leukocytes (VLCs) in mouse tumours. DC:
dendritic cells; MF: macrophage.
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organs of tumour-bearing mice at very low frequencies (o0.2%).
Second, we have demonstrated that the tumour microenvironment
induces DC to differentiate in vivo into endothelial-like cells. We
injected BM-derived DCs labelled with a fluorochrome subcuta-
neously around tumours overexpressing VEGF. At 3 days
postinjection, fluorescent DCs microdissected by laser-capture
exhibited a 2.6- and 6.1-fold upregulation of CD31 and VE-
cadherin, respectively, compared to preinjection levels, while 7
days postinjection a 60- and 22-fold upregulation was noted,
respectively, by real-time quantitative PCR. Furthermore, VEGFR-
2 was upregulated 20 fold. Collectively, these data suggest that the
tumour microenvironment can induce the endothelialisation of
immature DCs, thus mimicking the transdifferentiation process
observed in vitro. In addition, we have observed that labelled bone
marrow-derived DCs assemble into neovessels in Matrigel plugs, a
process that can be blocked by addition of neutralising antibodies
against VEGFR-2. However, although they are generally used for
every kind of immunological studies, it is still possible that bone
marrow-derived DCs do not belong to the DC type naturally found
in tumours and possess more plasticity.
CONCLUDING REMARKS
The identification of DCs or DC precursors as bipotent cells has
important implications for the physiopathology and therapy of
tumours. As VLCs are an important host cell population affecting
tumour growth, important concerns emerge regarding the use of
intratumoural DC inoculation as a means for tumour vaccination
in the human. Similarly, if VLCs are inefficient APCs, what is their
exact role in immune tolerance of tumours? It is also intriguing to
hypothesise that DC precursors might turn into lymphatic
endothelial-like cells under the influence of VEGF-C, thus
contributing to tumour metastasis. Finally, important questions
arise on numerous issues. Which is the relative contribution of
VLCs to tumour vascularisation? At which point of tumour
development is it more relevant? Is the contribution of VLCs to
vasculogenesis organ-dependent or affects different tumours in
similar proportions? And most importantly, are VLCs contributing
to physiologic vascularisation? The existing evidence that en-
dothelium increases APC capabilities and specialised endothelium
may participate in maintenance of peripheral tolerance raises
intriguing questions on the ontology of endothelial cells in normal
tissues and the relationship of angiogenesis and peripheral
tolerance.
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